ISB 2001
Glenmark shares gain 2% as firm receives $700 million upfront payment from AbbVie deal
Glenmark Pharmaceuticals' shares surged following its subsidiary's $700 million upfront payment from AbbVie for an exclusive licensing agreement concerning IGI's lead drug candidate, ISB 2001. The deal grants AbbVie rights in key markets, while Glenmark retains commercialization in emerging regions.
Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P
S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVie Inc. This deal, concerning ISB 2001, is expected to significantly strengthen Glenmark's financial standing and liquidity, reversing a previous net debt.
Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugs
Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio and strengthening its branded business. By 2030, the company aims for 70% of its revenue to come from branded products, focusing on dermatology, respiratory, and oncology. A recent deal with AbbVie for its cancer drug ISB 2001 highlights this strategic shift.
Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800
Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001. Analysts see up to 29% more upside, with technical experts advising a ‘buy on dips’ strategy. The stock broke out from a key gap zone, and brokerages like Motilal Oswal see targets up to Rs 2,800.
Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investors
The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing deal with U.S. pharma giant AbbVie for its cancer drug, ISB 2001.
Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation play
Glenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“validates key elements” of the company’s R&D platform and unlocks significant commercial potential.
- Go To Page 1
Stocks in news: DMart, IREDA, TCS, ZEE, HUL, Glenmark Pharma
Markets declined on weekly expiry day, with several companies in focus due to earnings and news. TCS reported a 6% profit increase, while IREDA's profit fell by 36%. Zee failed to secure shareholder votes for fundraising. HUL appointed Priya Nair as CEO, and Glenmark Pharma partnered with AbbVie for ISB 2001.
Glenmark Pharma hits 10% upper circuit, scales fresh 52-week high on $700 mn cancer drug deal
Glenmark Pharma Share Price: Glenmark Pharmaceuticals' shares soared after its subsidiary, Ichnos Glenmark Innovation, inked a global licensing agreement with AbbVie for its cancer drug, ISB 2001. AbbVie gains exclusive rights in major markets, while Glenmark retains rights for emerging markets. The deal includes a $700 million upfront payment and potential milestone payments, highlighting the drug's promise in treating multiple myeloma.
Glenmark, AbbVie ink $700 million drug licensing deal
Glenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targeting cancer and autoimmune diseases. The deal, potentially worth up to USD 2 billion, grants AbbVie exclusive rights in major markets, while Glenmark will focus on emerging markets.
Glenmark’s blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.
Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drug
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a 'Buy' rating.
US prospects, new drugs make Glenmark look better
Glenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 applications pending at various stages in the approval process.
Stocks to buy: L&T remains BNP Paribas' top pick; HSBC upgrades Glenmark to buy
Nomura, BNP Paribas, and HSBC have issued updated recommendations on Shree Cement, Larsen & Toubro (L&T), and Glenmark Pharma, emphasizing potential upside opportunities for investors.
Hot Stocks: 4 stocks that may give returns between 17-27%
Analysts recommend stocks such as HDFC Bank, Glenmark Pharmaceuticals, Tata Steel, and Samvardhana Motherson, expecting returns between 17% and 27%. Improvements in growth, favorable risk-reward, valuation comfort, and positive market outlooks drive their optimistic projections.
Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35%
Glenmark Pharmaceuticals Q3 Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY. Revenue surged 35% to ₹3,388 crore, with strong growth in India and Europe, while EBITDA stood at ₹600 crore with a 17.7% margin.
PM Modi to participate in ISB Hyderabad event on May 26; inaugurate, lay foundation stone of 11 projects in Tamil Nadu
Modi will visit Hyderabad and Chennai on May 26 and around 2 PM, will participate in the celebration of completion of 20 years of ISB Hyderabad and address the graduation ceremony of Post Graduate Programme class of 2022, the PMO said.
Promoter shareholding falling in non-family firms, rising in family ones: Study
The research study attempted to give a bird's eye view of the shareholding pattern of listed Indian firms.
Family firms up stake over last decade in India: Research
It seems to imply that the engine of growth of Indian businesses would not be dependent on overseas or other promoter categories.
Rajendra Srivastava of SMU to be new dean of Indian School of Business
The next dean of the Indian School of Business will be Rajendra Srivastava, 64, provost and deputy president of academic affairs at Singapore Management University.
Ashish Sonal's journey from Army to risk managemnet firm
After a stint in the army and a job with a risk management firm, Ashish Sonal started his own consultancy, which earned him Rs 9.9 cr this year.
'Move away from placement mania'
Would securing placements pose challenges for leading business schools in the country? Ajit Rangnekar, Dean of ISB, does not think so.
ISB exec board meets tomorrow; likely to choose new chairman
The executive board of Indian School of Business which will meet tomorrow in Hyderabad is likely to appoint a new Chairman, after the biz school's founder Rajat Gupta stepped down amid insider trading charges in the US.
MIT Sloan collaborating with ISB Hyderabad
MIT Sloan is heading up for a new collaboration with Business schools in India, by entering into a partnership with Indian School of Business, Hyderabad.
Three new directors to join ISB board
Hyderabad-based Indian School of Business appointed three new directors to join the existing near thirty-member board, the dean of the institute said.
ISB moves up to 15th in top-100 B-school list
For the second year in a row, Indian School of Business, Hyderabad has been the only Indian management institute that has made it to the Financial Times Global MBA ranking of the top 100 Bschools across the world.
ISB to launch second campus in Mohali
The country's leading business school, the Indian School of Business (ISB), is setting up another campus at Mohali in Punjab in an agreement with the Punjab Government and four corporate giants -- Max India, Bharti, Hero and Punj Llyod.
North to get its own ISB, courtesy four biz honchos
Four leading Delhi-based industrialists-Sunil Mittal, BM Munjal, Analjit Singh and Atul Punj have joined hands to bring the ISB to the north. Top business schools in India
ISB to provide training to Areva executives
Areva Group has chosen Indian School of Business, Hyderabad to provide training to its global executives through its specially designed programme in finance.
ISB not knowtowing before regulator
Top B-School snubs regulator, lobbying for accreditation from US panel.
Load More
